Arrowhead Research this week announced that it intends to raise $36 million through a private offering of roughly 14.3 million shares plus 9,900 shares of convertible preferred stock.

The common stock will be priced at $1.83 apiece, and the preferred shares are priced at $1,000 each and are convertible into shares of common stock at a price of $1.83 per share.

Arrowhead said that the offering is expected to close by May 3.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.